Vijayveer Pamar, MD
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1407853963
Payments from drug & device makers
Across 2,066 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$5K
- Mannkind Corporation$4K
- Novo Nordisk$4K
- AstraZeneca$4K
- Medtronic$3K
- Tandem Diabetes Care, Inc.$3K
- plus $26K from 54 others
What the payments were for
- Speaking & faculty fees$2,5505%
- Travel & lodging$120%
- Food & beverage$46,65395%
- Education$720%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$3,289
- CeQur Simplicity$2,070
- iLet Bionic Pancreas$1,872
- t:slim X2 insulin pump$1,700
- AFREZZA$1,354
- MINIMED 780G$1,290
- FARXIGA$1,074
- t-slim insulin pump$850
- FREESTYLE LIBRE 3$519
- INPEN SMART INSULIN DELIVERY SYSTEM$502
- t:slim X2 Insulin Pump with Control-IQ$476
- DEXCOM CGM$327
- iLet Insulin Infusion Kit Inset$309
- iLet Insulin Infusion Kit Contact Detach$309
- EVERSENSE E3 SENSOR KIT - RETAIL$282
- TWIIST$266
- EVENITY$243
- Ozempic$228
- DEXCOM G7 GSS (161)$150
- DEXCOM STELO GLUCOSE BIOSENSOR$150
How this compares
$49,347 in reported general payments places this provider in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 245 | $385,983 |
| MounjaroTirzepatide | 265 | $376,015 |
| TrulicityDulaglutide | 140 | $233,531 |
| JardianceEmpagliflozin | 76 | $91,161 |
| ProliaDenosumab | 42 | $71,587 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 46 | $64,947 |
| FarxigaDapagliflozin Propanediol | 51 | $53,367 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $49,400 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $45,999 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $43,127 |
| Humalog Kwikpen U-200Insulin Lispro | 19 | $40,702 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $36,067 |
| Novolog FlexpenInsulin Aspart | 91 | $33,993 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 34 | $32,221 |
| RybelsusSemaglutide | 21 | $30,371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $2,600 | $621,087444 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $3,875 | $428,944291 claims |
| Boehringer IngelheimJardiance | $1,399 | $91,16176 claims |
| AmgenProlia | $1,803 | $71,58742 claims |
| AstraZenecaFarxiga | $3,824 | $53,36751 claims |
| MerckJanumet Xr, Januvia | $469 | $52,32549 claims |
| Mannkind CorporationAfrezza | $3,902 | $29,96514 claims |
| Cequr CorporationCequr Simplicity | $2,070 | $13,43023 claims |
| AbbVieSynthroid | $999 | $11,644122 claims |
| Sanofi-aventis U.S. LLCLantus | $1,287 | $4,86319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in San Antonio
- Mark KipnesSan Antonio$10.3M
- Ralph DefronzoSan Antonio$4.8M
- Eugenio CersosimoSan Antonio$4M
- Devjit TripathySan Antonio$1.5M
- Carolina Solis-HerreraSan Antonio$1.3M
- Firas AkhrassSan Antonio$900K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.